Abstract: A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of the liquid pharmaceutical composition.
Abstract: Biological materials such as vaccines can be stabilized in certain glassy materials soluble in water. It has been proposed to form these glassy materials as a powder suspended in a non-aqueous liquid for injection into a patient. This method is complicated by the need to find suitable compatible liquids and to stop the glassy particles from congregating in liquid. These problems have been obviated by supporting the glassy material on a porous membrane remote from the eluant. When the biological material requires administration, the eluant can be passed across the membrane dissolving the glass and causing the substance to be carried by the liquid into the patient.
Type:
Grant
Filed:
November 21, 2006
Date of Patent:
September 2, 2014
Assignee:
NOVA Bio-Pharma Technologies Limited
Inventors:
Samodh de Costa, Bruce Roser, Shevanti Sen